TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23121563
Drug: Hb concentration
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hb concentration of 7·3 g dL(‐1) (restrictive group)
Study: 23121563
Drug: Hb concentration
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hb concentration of 8·9 g dL(‐1) (liberal group)
Study: 20354452
Drug: 6 mg/m
Normalized name: phenol 6 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/m MMC on day 1 and 125 mg/m irinotecan on days 2 and 9 (arm A)
Study: 20354452
Drug: 3 mg/m
Normalized name: urea 0.3 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/m MMC on days 1 and 8 and 125 mg/m irinotecan on days 2 and 9 (arm B)
Study: 1918553
Drug: Thermal biofeedback
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal biofeedback (TBF) treatment with regular home practice (group 1)
Study: 1918553
Drug: Thermal biofeedback
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal biofeedback (TBF) treatment without home practice (group 2)
Study: 6233335
Drug: Isotretinoin 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin 1.0 mg/kg/day
Study: 23110500
Drug: Diethylstilbestrol (DES)
Normalized name: Diethylstilbestrol
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylstilbestrol (DES) 1-3 mg daily with 75 mg aspirin
Study: 18837197
Drug: Electrical Twitch‐Obtaining
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical Twitch‐Obtaining Intramuscular Stimulation (eToims) using ET127 system, 3 Hz, 4 stimuli/site
Study: 16247790
Drug: CHOP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP with 80 mg/day of valsartan
Study: 1690068
Drug: Indoramin 20
Normalized name: indoramin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin 20 mg bd
Study: 1690068
Drug: Indoramin 20
Normalized name: indoramin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin 20 mg nocte
Study: 7084142
Drug: Diazepam solution
Normalized name: diazepam Oral Solution
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazepam solution 20 mg administered rectally
Study: 25592561
Drug: Intensified post-operative
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified post-operative chemotherapy (SIOPWT2001)
Study: 25592561
Drug: Historical control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical control chemotherapy (SIOP93-01)
Study: 25592561
Drug: Intensified treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified treatment in Stage I (SIOPWT2001)
Study: 25592561
Drug: Historical control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical control treatment in Stage I (SIOP93-01)
Study: 20071596
Drug: ATV 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATV 300 mg with ritonavir (RTV) 100 mg (ATV300/r, n = 95)
Study: 20071596
Drug: ATV 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATV 400 mg (ATV400; n = 105)
Study: 15642080
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg/day added to simvastatin 20 mg/day
Study: 15642080
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg/day (doubling the dose of simvastatin)
Study: 12140204
Drug: Oral aldose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral aldose reductase inhibitor (ONO-2235)
Study: 7006442
Drug: ICI 35868
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 35868 (Diprivan) 1-2 mg/kg
Study: 7006442
Drug: Althesin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Althesin 0.5 ml/kg
Study: 29716660
Drug: Blended psychosocial
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended psychosocial support program based on Acceptance and Commitment Therapy, consisting of 1 face-to-face contact, 6 online guided modules, and 1 telephone contact over 8 weeks.
Study: 24415271
Drug: Zofenopril 30
Normalized name: zofenopril 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zofenopril 30 mg plus HCTZ 12.5 mg
Study: 24415271
Drug: Irbesartan 150
Normalized name: irbesartan 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 150 mg plus HCTZ 12.5 mg
Study: 22764601
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg/d, PO in the morning)
Study: 15804294
Drug: Histamine concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine concentrations (0.1, 1.0, and 10 mg/ml)
Study: 12483236
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg CHX tablets
Study: 12483236
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg CHX tablets
Study: 2077497
Drug: meperidine 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: meperidine 0.50 mg/lb
Study: 2077497
Drug: meperidine 1.00
Approvals — FDA: no, EMA: no, PMDA: no
Description: meperidine 1.00 mg/lb
Study: 2077497
Drug: meperidine (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: meperidine (highest dose)
Study: 31688449
Drug: Pooled antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled antagonist group (haloperidol, flupentixol, olanzapine)
Study: 31688449
Drug: First-generation antipsychotics
Normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation antipsychotics (pooled)
Study: 28890299
Drug: Fluticasone/formoterol (125/6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone/formoterol (125/6 mcg BD)
Study: 28890299
Drug: Budesonide/formoterol (200/6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (200/6 mcg BD)
Study: 17959530
Drug: Amikacin administration
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin administration at 3-4 h postburn (group A)
Study: 17959530
Drug: Amikacin administration
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin administration at 10 h postburn (group B)
Study: 17959530
Drug: Amikacin administration
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin administration at 20 h postburn (group C)
Study: 17959530
Drug: Amikacin administration
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin administration at 30 h postburn (group D)
Study: 11585103
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment guided by plasma levels of N-BNP
Study: 11585103
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment based on clinical criteria
Study: 9686773
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg efaroxan, given three times per day
Study: 2685934
Drug: Interstitial Ir‐192
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interstitial Ir‐192 boost dose to the tumor bed immediately following resection
Study: 30451147
Drug: Mediterranean lemonade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean lemonade (ML)
Study: 25956954
Drug: Intramuscular phloroglucinol
Normalized name: phloroglucinol
DrugBank: Phloroglucinol (DB12944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular phloroglucinol (80 mg)
Study: 25956954
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (400 mg)
Study: 21807831
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of COSP and CMHA services
Study: 19523013
Drug: Lecozotan 0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lecozotan 0.1, 0.25, 0.5, 1 and 5 mg q12h
Study: 19523013
Drug: Lecozotan 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lecozotan 0.5 mg and 5 mg q12h
Study: 19523013
Drug: Single-dose lecozotan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose lecozotan 2, 5 and 10 mg
Study: 15608803
Drug: Age-specific insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Age-specific insulin resistance rates
Study: 11763111
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg pyridostigmine bromide (PB) every 8 hours for 13 doses
Study: 11763111
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg pyridostigmine bromide (PB) every 8 hours for 13 doses
Study: 9750974
Drug: Individual cognitive‐behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive‐behavior therapy (11 sessions)
Study: 7995616
Drug: Intranasal (D‐Ser6)‐gonadotrophin‐releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal (D‐Ser6)‐gonadotrophin‐releasing hormone (GnRH) analogue (buserelin) administered at a mean dose of 25 micrograms/kg/day for a mean period of 14 months
Study: 24159562
Drug: Amiodarone (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (median dose 300 mg)
Study: 11208684
Drug: Implantable cardioverter-defibrillator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable cardioverter-defibrillator therapy
Study: 18481710
Drug: Xingnao Kaiqiao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xingnao Kaiqiao acupuncture (once each day, for 4 weeks) + routine treatment of western medicine
Study: 18481710
Drug: Routine acupuncture
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine acupuncture + routine treatment of western medicine
Study: 11967729
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil (10-20 mg once daily)
Study: 11967729
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil (20-40 mg once daily)
Study: 11967729
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil (5-20 mg once daily)
Study: 10101728
Drug: D-fenfluramine (D-FEN)
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-fenfluramine (D-FEN) 30 mg PO
Study: 758705
Drug: Standard postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard postoperative fluid therapy (Control)
Study: 31888626
Drug: Intravenous C1‐INH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous C1‐INH (50 IU/kg)
Study: 31888626
Drug: Intravenous C1‐INH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous C1‐INH
Study: 29458749
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ferric carboxymaltose (FCM)
Study: 22810740
Drug: Preventive therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive therapy with pantogam at a mean dose of 1.8 g/daily
Study: 22810740
Drug: Cessation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cessation therapy with pantogam at a mean dose of 1.2 g/daily
Study: 17697863
Drug: Alpha-linolenic acid
Normalized name: Alpha-linolenic Acid
DrugBank: alpha-Linolenic acid (DB00132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-linolenic acid (ALA) supplementation via flaxseed oil capsules (increasing ALA to 5% of total energy intake) for 8 weeks.
Study: 16224843
Drug: Intra-operative (Iop)
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-operative (Iop) group received 0.5 mg/kg pethidine intravenously at the time of fascia closure
Study: 16224843
Drug: Post-operative (Pop)
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative (Pop) group received 0.5 mg/kg pethidine intravenously on arrival in the post‐anaesthesia care unit
Study: 7789662
Drug: Oral sensorimotor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sensorimotor therapy for 10 weeks
Study: 7789662
Drug: Oral sensorimotor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sensorimotor therapy for 20 weeks
Study: 7789662
Drug: Oral sensorimotor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sensorimotor therapy (10 and 20 weeks)
Study: 31856903
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (CT) plus behavioral experiments (BEs)
Study: 31856903
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (CT) as usual
Study: 25891115
Drug: LCPUFA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCPUFA supplementation (DHA 300 mg/day, EPA 100 mg/day, ARA 120 mg/day)
Study: 21248159
Drug: Parenteral challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral challenge with MACP
Study: 11874551
Drug: 10% Intralipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% Intralipid (2 kcal min(‐1)) - Continuous infusion (CID)
Study: 11874551
Drug: 10% Intralipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% Intralipid (2 kcal min(‐1)) - Pulsatile infusion (PID)
Study: 10798029
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no handwashing agent mentioned)
Study: 8926741
Drug: Intravenous cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cocaine (25 mg, cocaine HCl)
Study: 8926741
Drug: Intranasal cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cocaine (32 mg, cocaine HCl)
Study: 8926741
Drug: Smoked cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoked cocaine (42 mg, cocaine base)
Study: 7009440
Drug: Aminophylline (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (6 mg/kg i.v.)
Study: 7009440
Drug: Salbutamol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (200 mcg per inhalationem)
Study: 27246705
Drug: Status quo
Normalized name: Statuss Green Reformulated Jan 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Status quo (zinc and ORS co-administered without bundling)
Study: 18300441
Drug: Compound betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compound betamethasone injection (1 ml, postaural, single injection)
Study: 12151964
Drug: Oxaliplatin 130
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 130 mg/m2 on day 1 and daily oral UFT 350 mg/m2 in 3 divided doses for 21 days, repeated every 21 days
Study: 3290517
Drug: Acyclovir 400
Normalized name: acyclovir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 400 mg orally twice daily (suppressive treatment)
Study: 3290517
Drug: Placebo (episodic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (episodic treatment)
Study: 3290517
Drug: Acyclovir (suppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (suppressive therapy)
Study: 3290517
Drug: Acyclovir (episodic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (episodic therapy)
Study: 28027810
Drug: IPV Vaccine
Normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPV Vaccine SSI
Study: 17554786
Drug: Cisplatin (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (7 mg/kg administered intraperitoneally on Days 0 and 21)
Study: 15008338
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of air abrasion and phosphoric acid etching
Study: 10764336
Drug: Intramuscular pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular pethidine (analgesia group)
Study: 8354027
Drug: Caffeine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (250 mg intravenously)
Study: 8354027
Drug: Nicotine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (4 mg chewing gum)
Study: 8354027
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of caffeine and nicotine
Study: 2941966
Drug: 5'‐dFUrd 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5'‐dFUrd 5 g/m2 as a 1‐h infusion for 5 days in 3 cycles at intervals of 4 weeks
Study: 2941966
Drug: 5'‐dFUrd 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5'‐dFUrd 3 g/m2 as a 1‐h infusion for 5 days in 3 cycles at intervals of 4 weeks
Study: 2941966
Drug: High-risk group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk group (cachectic patients and patients with a pathological EEG before treatment)
Study: 31259807
Drug: Ocriplasmin (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocriplasmin (0.125 mg)
Study: 27727279
Drug: A single
Normalized name: Hemoccult Sensa Single Slide
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single ultra-low dose of aldesleukin (0.101 × 106 IU/m2)
Study: 27727279
Drug: A single
Normalized name: Hemoccult Sensa Single Slide
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single ultra-low dose of aldesleukin (0.497 × 106 IU/m2)
Study: 27727279
Drug: Lowest doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest doses of aldesleukin (0.040 × 106 and 0.045 × 106 IU/m2)
Study: 27727279
Drug: A single
Normalized name: Hemoccult Sensa Single Slide
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single ultra-low dose of aldesleukin
Study: 22129171
Drug: Dipyridamole 200
Normalized name: dipyridamole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole 200 mg slow release twice daily
Study: 21374068
Drug: Arzoxifene 20
Normalized name: Arzoxifene
DrugBank: Arzoxifene (DB06249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arzoxifene 20 mg/day
Study: 12954577
Drug: Arzoxifene 50
Normalized name: Arzoxifene
DrugBank: Arzoxifene (DB06249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arzoxifene 50 mg/day
Study: 10983645
Drug: CSF drug
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CSF drug concentrations of RTV and SQV
Study: 8243699
Drug: Pharmacologic technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic technique (diluted vasopressin 20 U in 20 mL normal saline)
Study: 29426774
Drug: Ciprofloxacin 20
Normalized name: ciprofloxacin 200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 20 mg/kg/day
Study: 27416541
Drug: G5K solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: G5K solution
Study: 27416541
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Ringer's maleate solution)
Study: 26054178
Drug: Test group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test group (zinc lactate and magnolia bark extract tablets)
Study: 6357269
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo tablets)
Study: 8603445
Drug: 6-mercaptopurine (6MP)
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-mercaptopurine (6MP) dose escalation (increased in monthly 25% steps if 75 mg/m2 was tolerated without cytopenias)
Study: 8603445
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (without dose escalation)
Study: 8603445
Drug: Escalated doses
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalated doses of 6MP (30 children)
Study: 8603445
Drug: 6MP dose
Normalized name: 2-Amino 6MP
DrugBank: Tioguanine (DB00352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6MP dose escalation
Study: 1577927
Drug: Intravaginal micronized
Normalized name: Intravaginal contraceptives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal micronized progesterone (600 mg/day)
Study: 1577927
Drug: Intramuscular progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular progesterone in oil (50 mg/day)
Study: 6375610
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of phentermine resin (15 mg in the morning) and fenfluramine hydrochloride (30 mg before the evening meal)
Study: 6375610
Drug: Fenfluramine hydrochloride
Normalized name: fenfluramine hydrochloride
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine hydrochloride (20 mg three times a day)
Study: 6375610
Drug: Phentermine resin
Normalized name: phentermine resin
DrugBank: Phentermine (DB00191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phentermine resin (30 mg in the morning)
Study: 26407273
Drug: Quadrivalent Influenza
Normalized name: influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2021-2022]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent Influenza Vaccine (QIV)
Study: 26407273
Drug: Trivalent Influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent Influenza Vaccine (TIV)
Study: 24687003
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of segmental and prosody training
Study: 22426247
Drug: Adaptive design
Normalized name: Designer Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive design with dose escalation and cohort expansion
Study: 18042651
Drug: Ghrelin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ghrelin infusion (5 pmol x kg(‐1) x min(‐1))
Study: 15610655
Drug: Modern treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modern treatment strategies including chemotherapy and radiotherapy
Study: 15610655
Drug: Reduction of
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction of chemotherapy doses or cycles